Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Uterine Cervical Neoplasms 2Condylomata Acuminata 2Vomiting 1Nausea 1Breast Neoplasms 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 12Vaccines, Synthetic 9Vaccines 3Papillomavirus Vaccines 3Imiquimod 2Duration of Therapy 2human papillomavirus vaccine, L1 type 16, 18 1Viusid 1Vaccination 1Tuberculin 1Podophyllin 1PRA1 protein, Candida albicans 1Measles-Mumps-Rubella Vaccine 1Hepatitis B Vaccines 1Diathermy 1Cyclophosphamide 1Cryotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Condylomata Acuminata × Duration of Therapy × Clear all
NCT00092482 2017-03-22

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
3,882 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00517309 2017-03-22

FUTURE

Merck Sharp & Dohme LLC

Phase 3 Completed
1,877 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡